Status | Study |
Recruiting |
Study Name: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment Condition: Hairy Cell Leukemia (HCL) Chronic Lymphocytic Leukemia (CLL) Date: 2010-03-13 |
Recruiting |
Study Name: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2010-01-29 Interventions: Drug: Pentostatin 28 patients |
Terminated |
Study Name: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2009-06-17 Interventions: Drug: BL22 (CAT-3888) 30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5 |
Recruiting |
Study Name: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2009-06-17 Interventions: Drug: Cladribine Cladribine 0. |
Completed |
Study Name: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Condition: Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia Date: 2008-01-30 Interventions: Drug: Dasatinib Given PO |
Completed |
Study Name: A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia Condition: Hairy Cell Leukemia Date: 2007-12-21 Interventions: Biological: CAT 8015 (Moxetumomab Pasudotox) The dose level of the initial cohort will be 5 μg/kg s |
Recruiting |
Study Name: Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Condition: Leukemia Hairy Cell Leukemia Date: 2007-04-16 Interventions: Drug: Immunotoxin therapy Drug: CAT-8015 I |
Recruiting |
Study Name: 2CDA With Rituximab in Hairy Cell Leukemia Condition: Leukemia Date: 2006-12-14 Interventions: Drug: Cladribine 5.6 mg/m^2 by |
Active, not recruiting |
Study Name: LMB-2 to Treat Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2006-05-03 Interventions: Drug: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0. |
Completed |
Study Name: BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Condition: Leukemia Date: 2003-12-10 Interventions: Drug: BL22 Dosing via IV on Days 1,3, and 5. |